<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Memantine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01043</strong>&#160; (APRD00221)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Memantine is an amantadine derivative with low to moderate-affinity for <span class="caps">NMDA</span> receptors. It is a noncompetitive <span class="caps">NMDA</span> receptor antagonist that binds preferentially to <span class="caps">NMDA</span> receptor-operated cation channels. It  blocks the effects of excessive levels of glutamate that may lead to neuronal dysfunction. It is under investigation for the treatment of Alzheimer&#8217;s disease, but there has been no clinical support for the prevention or slowing of disease progression.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01043/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01043/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01043.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01043.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01043.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01043.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01043.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01043">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Memantina</td><td>Spanish</td><td>INN</td></tr><tr><td>Memantine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN</td></tr><tr><td>Memantinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Memantine Hydrochloride</strong>
          <div class="cas">41100-52-1</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000456/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000456/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: LDDHMLJTFXJGPI-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 215.144077416</li>
              <li>Average Mass: 215.763</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000456">DBSALT000456</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Abixa</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Akatinol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Axura</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ebixa</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Memox</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Namenda</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/dopamine-agents">Dopamine Agents</a></li>
<li><a href="/mesh/antiparkinson-agents">Antiparkinson Agents</a></li>
<li><a href="/mesh/excitatory-amino-acid-antagonists">Excitatory Amino Acid Antagonists</a></li>
<li><a href="/mesh/antidyskinetics">Antidyskinetics</a></li></ul></td></tr><tr><th>CAS number</th><td>19982-08-2</td></tr><tr><th>Weight</th><td>Average: 179.3018<br>Monoisotopic: 179.167399677</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>21</sub>N</td></tr><tr><th>InChI Key</th><td>BUGYDGFZZOZRHP-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">3,5-dimethyladamantan-1-amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC12CC3CC(C)(C1)CC(N)(C3)C2</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organonitrogen Compounds</td></tr><tr><th>Class</th><td>Amines</td></tr><tr><th>Subclass</th><td>Polyamines</td></tr><tr><th>Direct parent</th><td>Polyamines</td></tr><tr><th>Alternative parents</th><td>Monoalkylamines</td></tr><tr><th>Substituents</th><td>primary aliphatic amine; primary amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the polyamines. These are compounds containing more than one amine group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of moderate to severe dementia of the Alzheimer's type.</td></tr><tr><th>Pharmacodynamics</th><td>Memantine, an amantadine derivative, is an NMDA receptor antagonist used in the treatment of Alzheimer's disease. It differs from traditional agents used in Alzheimer's disease by acting on glutamatergic neurotransmission, rather than cholinergic. There is some evidence that dysfunction of glutamatergic neurotransmission, manifested as neuronal excitotoxicity, is involved in the aetiology of Alzheimer's disease (Cacabelos et al., 1999). As such, targeting the glutamatergic system, specifically NMDA receptors, was a novel approach to treatment in view of the limited efficacy of existing drugs targeting the cholinergic system. A systematic review of randomised controlled trials found that memantine has a positive effect on cognition, mood, behaviour, and the ability to perform daily activities. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer's disease.</td></tr><tr><th>Mechanism of action</th><td>Memantine exerts its action through uncompetitive NMDA receptor antagonism, binding preferentially to the NMDA receptor-operated cation channels. Prolonged increased levels of glutamate in the brain of demented patients are sufficient to counter the voltage-dependent block of NMDA receptors by Mg<sup>2+</sup> ions and allow continuous influx of Ca<sup>2+</sup> ions into cells, ultimately resulting in neuronal degeneration. Studies suggest that memantine binds more effectively than Mg<sup>2+</sup> ions at the NMDA receptor, and thereby effectively blocks this prolonged influx of Ca<sup>2+</sup> ions through the NMDA channel whilst preserving the transient physiological activation of the channels by higher concentrations of synaptically released glutamate. Thus memantine protects against chronically elevated concentrations of glutamate. Memantine also has antagonistic activity at the type 3 serotonergic (5-HT<sub>3</sub>) receptor with a potency that is similar to that at the NMDA receptor, and lower antagonistic activity at the nicotinic acetylcholine receptor. This drug has no affinity for &#947;-aminobutyric acid (GABA), benzodiazepine, dopamine, adrenergic, histamine, or glycine receptors or for voltage-dependent calcium, sodium, or potassium channels.</td></tr><tr><th>Absorption</th><td>Well absorbed orally with a bioavailability of approximately 100%. Peak plasma concentrations are reached in 3-7 hours. Food has no effect on absorption.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>9 to 11 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>45%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Excreted largely unchanged. About 20% is metabolized to 1-amino-3-hydroxymethyl-5-methyl-adamantane and 3-amino-1-hydroxy-5,7-dimethyl-adamantane.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Memantine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00666">1-amino-3-hydroxymethyl-5-methyl-adamantane</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/687">Details</a></td></tr><tr><td>Memantine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00705">3-amino-1-hydroxy-5,7-dimethyl-adamantane</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/726">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Memantine undergoes partial hepatic metabolism. About 48% of administered drug is excreted unchanged in urine; the remainder is converted primarily to three polar metabolites which possess minimal NMDA receptor antagonistic activity: the N-glucuronide conjugate, 6-hydroxy memantine, and 1-nitroso-deaminated memantine.  It is excreted predominantly in the urine, unchanged.</td></tr><tr><th>Half life</th><td>60-100 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Side effects include pain, abnormal crying, leg pain, fever, increased apetite. Adverse drug reactions include: dizziness, confusion, headache, hallucinations, tiredness. Less common side effects include: vomiting, anxiety, hypertonia, cystitis, and increased libido. Doses of up to 400 mg have been tolerated.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9939</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9823</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6082</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6403</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.82</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7555</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7774</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8213</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.6153</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5319</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9327</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9281</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.872</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6795</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6945
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7426
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9633
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.3455 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9839
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6818
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Forest laboratories inc</li>
<li>Sun pharmaceutical industries ltd</li>
<li>Dr reddys laboratories ltd</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Coupler Enterprises Inc.</li>
<li><a href="http://www.frx.com">Forest Laboratories Inc.</a></li>
<li><a href="http://www.forestpharm.com">Forest Pharmaceuticals</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.lundbeckinc.com">Lundbeck Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li>Vangard Labs Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>10mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00819">Acetazolamide</a></td><td>Possible increased levels of memantine</td></tr><tr><td><a href="/drugs/DB00915">Amantadine</a></td><td>Increased risk of CNS adverse effects with this association</td></tr><tr><td><a href="/drugs/DB01144">Diclofenamide</a></td><td>Possible increased levels of memantine</td></tr><tr><td><a href="/drugs/DB01221">Ketamine</a></td><td>Increased risk of CNS adverse effects with this association</td></tr><tr><td><a href="/drugs/DB00703">Methazolamide</a></td><td>Possible increased levels of memantine</td></tr><tr><td><a href="/drugs/DB01390">Sodium bicarbonate</a></td><td>Possible increased levels of memantine</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li></ul></td></tr></tbody></table>